Santhera Pharmaceuticals Holding AG of Switzerland has reported further positive data from a Phase 3 trial of a new treatment for Duchenne Muscular Dystrophy (DMD), a genetic disease that causes severe degeneration of the muscle. ---Subscribe to MedNous to access this article--- Company News Clinical Research
